Key Takeaways OPKO Health targets 30% fiscal 2026 growth, backed by RAYALDEE and pipeline momentum.RAYALDEE generated $21.0M in sales in first nine months of 2025, supported by broad U.S. distributioOPK advances Phase 1/2 trials and expands deals with Entera, Regeneron and Merck.OPKO Health, Inc. (OPK) is well-poised for growth in the coming quarters, supported by the potential of RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic partnerships. However, stiff comp ...

Opko Health Inc. (NASDAQ:OPK) is one of the best high-return penny stocks to buy right now. On February 10, analysts at H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK) and settled on a $3 price target. The positive stance underscores the research firm’s confidence amid progress in the company’s biological partnerships. Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation The company’s subsidiary, OPKO Health, has already expanded its collaboration with Entera B ...

MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to ...

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replacement therapies, to advance the first oral long-acting PTH analog (LA-PTH) treatment for patients with hypoparathyroidism, in the form of a once-daily tablet. The two companies have also jointly decided to accelerate development on this medication and expect to file an Inves ...

Core Viewpoint - OPKO Health and Entera Bio are expanding their collaboration to develop innovative oral peptide therapies, including a long-acting PTH analog for hypoparathyroidism and an oral oxyntomodulin for metabolic disorders, with IND applications expected in late 2026 [3][4][5]. Group 1: Collaboration and Development Programs - The collaboration between OPKO and Entera aims to advance the first oral long-acting PTH analog (LA-PTH) as a once-daily tablet for hypoparathyroidism, with an IND application planned for late 2026 [3][4]. - The companies are also developing an injectable and oral oxyntomodulin (OXM) for metabolic and fibrotic disorders, with initial Phase 1 data from the injectable form expected in late 2026 [1][8]. - Under the expanded collaboration agreement, both companies will hold a 50% ownership interest in the LA-PTH program and share development costs equally, while maintaining a 60%/40% ownership structure for the oral OXM program [5]. Group 2: Key Personnel Changes - Steve Rubin, an industry veteran with extensive experience in corporate governance and drug development, has joined Entera's board of directors, replacing Gerry Ostrov [2][6]. Group 3: Clinical Data and Market Potential - Preclinical data for the oral LA-PTH program suggests it could transform treatment for hypoparathyroidism, which currently relies on daily injections of the only approved PTH replacement therapy [7]. - Entera's previous clinical data for its EB612 program indicated significant reductions in calcium supplement use and maintenance of serum calcium levels, although the regimen required multiple daily doses [7]. - The oral oxyntomodulin is positioned as a dual GLP-1/glucagon agonist with potential benefits for obesity and metabolic disorders, with no approved dual agonists currently available [8].

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

Group 1 - The article does not contain any relevant content regarding company or industry insights [1]

OPKO Health Conference Call Summary Company Overview - **Company**: OPKO Health - **Key Participants**: - Elias Zerhouni - President - Adam Logal - CFO - **Industry**: Biotechnology and Clinical Diagnostics Core Business Components - OPKO Health operates a diverse range of businesses, including: - Clinical diagnostics through BioReference Health - Biotech operations via ModeX Therapeutics, focusing on therapeutics and divesting from clinical diagnostics to improve profitability [6][15] Financial Performance and Strategy - OPKO has divested approximately 40% of its clinical diagnostic business to enhance profitability, focusing on operations in New York and New Jersey [6][15] - The company is nearing break-even and profitability with its remaining clinical diagnostic business, particularly with the 4Kscore cancer diagnostic test, which has shown over 15% growth in testing [7][17] - Guidance for 2026 indicates a projected revenue growth of 3%-5% from a base of approximately $300 million, with a focus on operating efficiency rather than deep investment in commercial operations [18] Key Products and Developments - **4Kscore Test**: - Aids in identifying patients at high risk for aggressive prostate cancer, with a market potential of $25-$30 million [20][21] - Recently received FDA clearance to remove the requirement for a digital rectal exam, potentially increasing adoption [21] - **ModeX Therapeutics**: - Licensed an Epstein-Barr Virus (EBV) vaccine to Merck for $50 million upfront and potential milestones of $870 million [9][10] - The vaccine is in phase one trials, with significant potential for treating cancer and multiple sclerosis [10][25] - **Pipeline Products**: - MDX-2001: A cancer solid tumor product nearing phase 1B trials, targeting multiple cancer types [11][32] - MDX-2004: A trispecific antibody aimed at rejuvenating the immune system, currently in clinical trials [12][42] - Collaboration with Regeneron to develop multiple programs in obesity, metabolism, and cancer [13][52] Milestones and Future Outlook - The company anticipates significant milestones tied to the progression of its vaccine and therapeutic candidates, with potential financial milestones upon entering phase two trials [27][31] - The partnership with Regeneron is expected to yield candidates by the end of the year or early next year, with a focus on combination therapies [53][54] Risk Management and Clinical Trials - OPKO is managing risks associated with clinical trials, particularly concerning cytokine release syndrome (CRS) through established protocols and dose management strategies [36][39] - The company is focused on ensuring safety and efficacy in its trials, with ongoing assessments to determine the most responsive cancer types for its therapies [32][35] Conclusion - OPKO Health is strategically repositioning itself towards a more therapeutics-focused model while maintaining a profitable clinical diagnostics segment. The company is poised for growth with a rich pipeline of products and strategic partnerships that could lead to significant advancements in the biotech space over the next few years [15][30]

MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors section ...

Core Viewpoint - OPKO Health, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, indicating its active engagement with investors and the healthcare community [1] Company Participation - Management will host one-on-one meetings with investors during the conference [1] - A fireside chat is scheduled for January 14th at 1:30 p.m. Pacific time, which will be webcast live and available for replay [1][2] Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing industry-leading positions in large, rapidly growing markets [3] - The company leverages its expertise in discovery, development, and commercialization, along with novel and proprietary technologies [3]